Response to "Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis". Response to related letter

Nefrologia (Engl Ed). 2024 May-Jun;44(3):444-446. doi: 10.1016/j.nefroe.2023.10.010. Epub 2024 Jun 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptides* / analogs & derivatives
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Immunoglobulin Fc Fragments* / therapeutic use
  • Obesity* / complications
  • Peritoneal Dialysis*
  • Recombinant Fusion Proteins* / therapeutic use

Substances

  • dulaglutide
  • Glucagon-Like Peptides
  • Recombinant Fusion Proteins
  • Immunoglobulin Fc Fragments
  • Hypoglycemic Agents

Associated data

  • ClinicalTrials.gov/NCT03819153